Top Markets
#1 Merlin's Seal BTC Merlin's Seal BTC +41.87%
#2 0G 0G +29.33%
#3 SAFEcoin SAFEcoin +22.40%
#4 VVS Finance VVS Finance +20.47%
#5 Seeker Seeker +20.05%
#6 Zora Zora +19.92%
#7 Full Moon Full Moon +17.70%
#8 Concordium Concordium +17.06%
#9 Notcoin Notcoin +15.26%
#10 Axelar Axelar +15.23%
Coin of the day
Merlin's Seal BTC Merlin's Seal BTC
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
Classifica tra le azioni #13173
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Prezzo delle azioni
$8.46
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$514.33M
Variazione (1 giorno)
-2.08%
Variazione (1 anno)
128.03%
Paese
US
Scambia Kyverna Therapeutics, Inc. (KYTX)

Categoria

Healthcare
Ricavi di Kyverna Therapeutics, Inc. (KYTX)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Kyverna Therapeutics, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Kyverna Therapeutics, Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH